Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has issued an announcement.
Recce Pharmaceuticals Ltd. has received Human Research Ethics Committee approval to expand its Phase II clinical trial for the RECCE® 327 Topical Gel, allowing up to 20 additional diabetic patients with foot infections to participate. This decision follows promising Phase II results, where the gel showed high efficacy in treating acute bacterial skin and skin-structure infections, including diabetic foot ulcer infections. The study aims to address the urgent need for effective treatments, as diabetic foot infections have high recurrence rates and can lead to severe complications. The trial will run alongside Recce’s Phase 3 programs in Indonesia and Australia, further supporting the company’s clinical momentum and data portfolio.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is a leading developer in the pharmaceutical industry, focusing on creating a new class of synthetic anti-infectives. The company is committed to addressing unmet medical needs, particularly in treating difficult-to-treat infections such as diabetic foot infections, using innovative treatments like the RECCE® 327 Topical Gel.
YTD Price Performance: -39.58%
Average Trading Volume: 206,124
Technical Sentiment Signal: Buy
Current Market Cap: A$78.45M
See more insights into RCE stock on TipRanks’ Stock Analysis page.